Geovax Labs Inc., of Atlanta, said the National Institute of Allergy and Infectious Diseases awarded the company a Small Business Innovative Research grant in support of its Zika vaccine development program. Read More
Drug prices were part of the conversation Wednesday as delegates to the 71st World Health Assembly asked the World Health Organization (WHO) to elaborate on a five-year roadmap to address the global shortage of, and access to, medicines and vaccines that's to be presented at next year's assembly. Read More
Eiger Biopharmaceuticals Inc., of Palo Alto, Calif., priced its public offering of 3.2 million shares at $12.50 per share for gross proceeds of $40 million. Read More
Call it the engineer's version of probiotics. Scientists at the Massachusetts Institute of Technology have engineered a device that combined bacteria and microelectronics to detect biological signals in the gut. Read More
A new understanding of how the almost 100-year-old ketogenic diet works to reduce seizures is guiding Bloom Science Inc. in its twin-pronged approach, which involves developing a medical food for epilepsy as well as an oral drug for orphan indications within the category. Read More
SHANGHAI – Reform is not a word that the Chinese government shies away from. That has been particularly true for China's pharmaceutical industry. Since 2015, the government has been tackling widespread and impressive reforms, not the least of which was joining the International Council of Harmonization (ICH) last summer, accelerating the country's ability to align its system with international norms. Read More
Kiniksa Pharmaceuticals Inc. and Scholar Rock Holding Corp. completed their journeys to the public markets, as Aptinyx Inc. – fresh off completion of its option deal with Allergan plc for a candidate to treat major depressive disorder – sought to follow in their footsteps. Read More
HONG KONG – Newly launched Chinese biotech Brii Biosciences is looking to use an experienced management team, partnerships and $260 million in initial funding to bring innovative medicines to its home market faster. Its initial focus will be infectious diseases. Read More
The Trump administration showered the FDA with love in its fiscal 2019 budget, but the Senate . . . not so much. With no debate Thursday, the Senate Appropriations Committee agreed to advance a spending package to the full Senate that would give the agency $5.4 billion in overall spending, even less than the $5.57 billion called for in a separate bill approved by the House Appropriations Committee last week. Read More
The FDA refusal to approve a new drug application for Recro Pharma Inc.'s lead non-opioid pain candidate, I.V. meloxicam, sent company shares (NASDAQ:REPH) plunging 54.7 percent lower to close at $5.36 on Thursday, amid what had been a flurry of precommercial preparations at the Malvern, Pa.-based company. Read More
